Ask the Psoriasis Expert

Psoriasis in 2018 It Was a Very Good Year

Topical Treatments

HP/TAZ Fixed Combination Study Design

HP/TAZ Fixed Combination Lotion Efficacy

HP 0.01% Lotion Phase 3 Trials

MC2-01 Cal BDP Cream PAD

How Will New Topical Treatments Impact Clinical Practice?

Tildrakizumab ReSURFACE Trials

Tildrakizumab in Patients With Inadequate Response to Etanercept at Week 28

Brodalumab in Patients Who Failed IL-17A Agents

Risankizumab UltIMMA Trials

Risankizumab Efficacy

Bimekizumab BE ABLE Phase 2 Trial

Mirikizumab 52-Week Efficacy in PASI 90 Nonresponders at Week 16

Oral TYK-2 Inhibitor Phase 2 Trial

How Will New Targeted Agents Fit Into Practice?

Comorbid Psoriatic Arthritis

Comorbid Inflammatory Bowel Disease

Pregnancy and Nursing Mothers

Go Team!

Concluding Remarks

Abbreviations